The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Affiliation
University of Padua, Department for Women's and Children's Health
Country
Italy
1. Current Status, Position
Dr. Daniele Donà is currently a pediatric infectious diseases consultant at the Department for Women’s and Children’s Health of the University of Padua, Italy. He is responsible for the pediatric antimicrobial stewardship programmes. He is also Assistant Professor at the Department for Women’s and Children’s Health.
2. Education
He studied medicine at the University of Padua Medical School and received Unrestricted licensure to practice medicine in 2009. In 2015, he finished his Residency in Pediatrics, and, in 2018, he obtained a PhD in Pediatric Infectious Diseases at the University of Padua.
Between 2016 and 2018, he also attended the Diploma in Pediatric Infectious Diseases at the Department for Continuing Education at the University of Oxford, Oxford (United Kingdom), and he obtained in Master of Science in Pediatric Infectious Diseases at the Department for Continuing Education at the University of Oxford, Oxford (United Kingdom). Between 2014 and 2016, he also worked as a pediatric Research Fellow in Pediatric Infectious Diseases at Children’s Hospital of Philadelphia, Philadelphia (United States), and between 2017-2019 he moved to London as a Research Fellow in Pediatric Infectious Diseases at St. George’s University of London, London (United Kingdom).
3. Research Area
He is a pediatrician with a strong interest in Pediatric Infectious Diseases. His main projects focus on antimicrobial resistance, antimicrobial stewardship and infection prevention and control in pediatrics. Furthermore, his area of interest is designing clinical trials of new and old antibiotics in high-income and low-income countries, in neonates and children with multidrug-resistance infections.
4. Conflict of interest
None